ArticleNature2021
Anti-tumour immunity induces aberrant peptide presentation in melanoma.
Open access · bronzeAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.
0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed
4.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 144 citations in OpenAlex.
- Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.British journal of cancer · 2023Trial
- Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer.Journal for immunotherapy of cancer · 2021Trial
- pXg: Comprehensive and Reliable Identification of MHC-I Antigens Using De Novo Peptide Sequencing and Immunotranscriptomic Datasets.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Mapping the functional dark proteome in cancer.Nature reviews. Cancer · 2026Review
- Global and specific mechanisms stimulate mistranslation in cancer.Nature cell biology · 2026Article
- Recoding by NNature communications · 2026Article
- Cobalt-mediated suppression of IFN-γ-JAK-STAT1 signaling reprograms IDO1-driven immunosuppression for metalloimmunotherapy.Science advances · 2026Article
- Tryptophan metabolism in tumor microenvironment and therapeutic implications.Journal of advanced research · 2026Review
- Translational resistance to amino acid starvation in breast cancer cells revealed by ribosome profiling.iScience · 2026Article
- Arginine Deprivation of ASS1-Deficient Cancers Drives Mistranslation and Shared Neoepitope Production.Cancer research · 2026Article
- LFPM inhibition of RING1-mediated p53Cell death and differentiation · 2026Article
- Histidine to glutamine substitutants, a regulated process that impacts cell survival and suggests histidine shortage in cancer.Cell death discovery · 2026Article
- Article
- Review
- Artemether and Euphorbia factor L9 suppress kynurenine production through distinct effects on tryptophan metabolism.The Biochemical journal · 2026Article
- A Stretchable, Transparent, Photothermally Stimulated Laser-Induced Graphene Patch for Noninvasive Skin Tumor Treatment.ACS nano · 2026Article
- Cancer neuroscience: signaling pathways and new therapeutic strategies for cancer.Signal transduction and targeted therapy · 2026Review
- Antibody screening for tumor and immune hotspot targets: The frontier of new methods and technologies.Journal of pharmaceutical analysis · 2026Review
- From ribosomopathies to therapeutic targets: ribosomal alterations in pediatric leukemogenesis and tumorigenesis.Frontiers in oncology · 2026Review
- Metabolic reprogramming as a driver of immune escape in melanoma: implications for immunotherapy.Frontiers in immunology · 2026Review
42 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
30 authors at 7 institutions in 4 countries.
Osnat Bartok *Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Abhijeet Pataskar *Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Remco Nagel *Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Maarja LaosDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Eden GoldfarbDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Deborah HayounDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Ronen LevyDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Pierre-Rene KörnerDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Inger Z M KreugerDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Julien ChampagneDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-8460-858X
Esther A ZaalBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0001-9890-7345
Onno B BleijerveldProteomics Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-9395-2347
Xinyao HuangDivision of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Juliana KenskiDivision of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Jennifer WargoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-3438-7576
Alexander BrandisLife Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
Yishai LevinThe Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel.
Orel MizrahiDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Michal AlonDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Sacha LebonDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Weiwen YangDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Morten M NielsenDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Noam Stern-GinossarDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.ORCID http://orcid.org/0000-0003-3583-5932
Maarten AltelaarBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, Utrecht, The Netherlands.
Celia R BerkersBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-0746-8565
Tamar GeigerDepartment of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Daniel S PeeperDivision of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-1293-3177
Johanna OlweusDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Yardena SamuelsDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. Yardena.Samuels@weizmann.ac.il.ORCID http://orcid.org/0000-0002-3349-7266
Reuven AgamiDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. r.agami@nki.nl.ORCID http://orcid.org/0000-0002-2848-2473
Weizmann Institute of Science · ILThe Netherlands Cancer Institute · NLOslo University Hospital · NOUtrecht University · NLErasmus MC · NLTel Aviv University · ILThe University of Texas MD Anderson Cancer Center · US
Funding
European Research Council
Abstract
Extensive tumour inflammation, which is reflected by high levels of infiltrating T cells and interferon-γ (IFNγ) signalling, improves the response of patients with melanoma to checkpoint immunotherapy
Indexed as
Antigen PresentationFrameshift MutationCell LineCodonFrameshifting, RibosomalHistocompatibility Antigens Class IHumansIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaMelanomaPeptidesProtein BiosynthesisProteomeRibosomesT-LymphocytesTryptophanCodonHistocompatibility Antigens Class IIDO1 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaPeptidesProteomeTryptophan
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.